Evidence map›Paper›PMID 36832333›Full record

ArticleChildren (Basel, Switzerland)2023

Efficacy of the Simeox

Dorota Sands, Katarzyna Walicka-Serzysko, Justyna Milczewska, Magdalena Postek, Natalia Jeneralska, Aleksandra Cichocka, Ewa Siedlecka, Urszula Borawska-Kowalczyk, Laurent Morin

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Children (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04084041 (Efficacy of the Simeox Airway Clearance Technology in the Treatment of Children With Clinically Stable Cystic Fibrosis- Cross-over Study With Randomization), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04084041 nacompletednot on this map

Efficacy of the Simeox Airway Clearance Technology in the Treatment of Children With Clinically Stable Cystic Fibrosis- Cross-over Study With Randomization

TypeinterventionalSponsorPhysio-AssistRan2019 to 2021Enrolled40ConditionsCystic Fibrosis in Children, Airway Clearance ImpairmentArmsSimeox, CCPT
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dorota SandsCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.
Katarzyna Walicka-SerzyskoCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.ORCID 0000-0002-6496-8737
Justyna MilczewskaCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.ORCID 0000-0003-3365-9963
Magdalena PostekCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.
Natalia JeneralskaCystic Fibrosis Centre, Pediatric Hospital, 05-092 Dziekanow Lesny, Poland.
Aleksandra CichockaCystic Fibrosis Centre, Pediatric Hospital, 05-092 Dziekanow Lesny, Poland.
Ewa SiedleckaCystic Fibrosis Centre, Pediatric Hospital, 05-092 Dziekanow Lesny, Poland.
Urszula Borawska-KowalczykCystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland.
Laurent MorinPhysioAssist, 34090 Montpellier, France.ORCID 0000-0002-7406-4838

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCystic fibrosis (CF) patients require regular airway clearance therapy (ACT). The aim of this study was to evaluate homecare therapeutic effects of a new ACT (Simeox

methodsForty pediatric CF patients (8-17 years old) with stable disease were randomized 1:1 in a single-center, prospective, open-label, cross-over trial into two groups: with or without Simeox

resultsA significant decrease in proximal airway obstruction (as supported by improvement in airway resistance at 20 Hz (R20Hz) and maximum expiratory flow at 75% of FVC (MEF75)) compared to the control group was observed after 1 month of therapy with the device. Lung-clearance index was stable in the study group, while it worsened in the control group. In addition, the device group demonstrated a significant increase in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) physical score. No side effects were identified during the study.

conclusionsSimeox

Indexed as

chest physiotherapycystic fibrosishomecare therapypulmonary function testSimeox

Identifiers

PMID36832333
PMCPMC9955024
OpenAlexW4317885343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.